"Karetov\u00E1, Debora" . "6"^^ . "Since 2008, internationally recognized guidelines have been in effect regarding the prevention and treatment of thromboembolic disease (TED). The national guidelines dealing with numerous aspects of thromboembolic disease are then based on these 8th ACCP Guidelines. However, new drugs, particularly in the prevention of TED, have been registered since the latest issue that alter the previous therapeutic practices. The development of new effective anticoagulant drugs has focused on direct thrombin inhibitors and direct factor Xa inhibitors. From the former group, dabigatran has been approved for clinical use, i.e. for the prevention of thromboembolic events in orthopaedics; from the latter group, rivaroxaban has been approved and apixaban is about to be registered in the Czech Republic. The other molecules have so far been in the phase of clinical testing (e. g. betrixaban, edoxaban, otamixaban). The results of studies conducted so far are very promising; for instance, when compared to low-molecular-wei"@en . . . . "Prevention and treatment of thromboembolic disease 2011"@en . . "Bultas, Jan" . "Prevence a l\u00E9\u010Dba tromboembolick\u00E9 nemoci 2011" . "RIV/00216208:11120/11:00003479!RIV12-MSM-11120___" . . "RIV/00216208:11120/11:00003479" . . "[F517DCDBD892]" . "Od roku 2008 jsou dosud v platnosti sv\u011Btov\u011B uzn\u00E1van\u00E1 doporu\u010Den\u00ED t\u00FDkaj\u00EDc\u00ED se prevence a l\u00E9\u010Dby tromboembolick\u00E9 nemoci (TEN). Od t\u011Bchto 8. ACCP (American College of Chest Physicians) guidelines se pak odv\u00EDjej\u00ED n\u00E1rodn\u00ED doporu\u010Den\u00ED, zab\u00FDvaj\u00EDc\u00ED se mnoha aspekty tromboembolick\u00E9 nemoci. Zejm\u00E9na v\u0161ak v prevenci TEN byly od posledn\u00EDho vyd\u00E1n\u00ED registrov\u00E1ny nov\u00E9 l\u00E9ky, kter\u00E9 m\u011Bn\u00ED dosavadn\u00ED l\u00E9\u010Debn\u00E9 praktiky. V\u00FDvoj nov\u00FDch \u00FA\u010Dinn\u00FDch antikoagulanci\u00ED se zam\u011B\u0159il na p\u0159\u00EDm\u00E9 inhibitory trombinu a p\u0159\u00EDm\u00E9 inhibitory faktoru Xa. Z prv\u00E9 skupiny je ji\u017E pro klinick\u00E9 u\u017Eit\u00ED, tj. prevenci tromboembolick\u00FDch p\u0159\u00EDhod v ortopedii, schv\u00E1len dabigatran (Pradaxa), rivaroxaban (Xarelto) a p\u0159ed registrac\u00ED v \u010CR je apixaban (Eliquis). Ostatn\u00ED molekuly jsou zat\u00EDm ve stadiu klinick\u00E9ho hodnocen\u00ED (nap\u0159. betrixaban, edoxaban, otomixaban). V\u00FDsledky dosavadn\u00EDch studi\u00ED jsou velmi slibn\u00E9, nap\u0159\u00EDklad p\u0159i srovn\u00E1n\u00ED s n\u00EDzkomolekul\u00E1rn\u00EDmi hepariny byl v profylaxi tromboembolick\u00FDch p\u0159\u00EDhod u operac\u00ED velk\u00FDch kloub\u016F rivaroxaban dvakr\u00E1t \u00FA\u010Dinn\u011Bj\u0161\u00ED proti enoxaparinu, v p"@cs . "2"^^ . "Prevence a l\u00E9\u010Dba tromboembolick\u00E9 nemoci 2011" . "223210" . "1"^^ . . . "thromboembolic disease; pharmacotherapy"@en . "Od roku 2008 jsou dosud v platnosti sv\u011Btov\u011B uzn\u00E1van\u00E1 doporu\u010Den\u00ED t\u00FDkaj\u00EDc\u00ED se prevence a l\u00E9\u010Dby tromboembolick\u00E9 nemoci (TEN). Od t\u011Bchto 8. ACCP (American College of Chest Physicians) guidelines se pak odv\u00EDjej\u00ED n\u00E1rodn\u00ED doporu\u010Den\u00ED, zab\u00FDvaj\u00EDc\u00ED se mnoha aspekty tromboembolick\u00E9 nemoci. Zejm\u00E9na v\u0161ak v prevenci TEN byly od posledn\u00EDho vyd\u00E1n\u00ED registrov\u00E1ny nov\u00E9 l\u00E9ky, kter\u00E9 m\u011Bn\u00ED dosavadn\u00ED l\u00E9\u010Debn\u00E9 praktiky. V\u00FDvoj nov\u00FDch \u00FA\u010Dinn\u00FDch antikoagulanci\u00ED se zam\u011B\u0159il na p\u0159\u00EDm\u00E9 inhibitory trombinu a p\u0159\u00EDm\u00E9 inhibitory faktoru Xa. Z prv\u00E9 skupiny je ji\u017E pro klinick\u00E9 u\u017Eit\u00ED, tj. prevenci tromboembolick\u00FDch p\u0159\u00EDhod v ortopedii, schv\u00E1len dabigatran (Pradaxa), rivaroxaban (Xarelto) a p\u0159ed registrac\u00ED v \u010CR je apixaban (Eliquis). Ostatn\u00ED molekuly jsou zat\u00EDm ve stadiu klinick\u00E9ho hodnocen\u00ED (nap\u0159. betrixaban, edoxaban, otomixaban). V\u00FDsledky dosavadn\u00EDch studi\u00ED jsou velmi slibn\u00E9, nap\u0159\u00EDklad p\u0159i srovn\u00E1n\u00ED s n\u00EDzkomolekul\u00E1rn\u00EDmi hepariny byl v profylaxi tromboembolick\u00FDch p\u0159\u00EDhod u operac\u00ED velk\u00FDch kloub\u016F rivaroxaban dvakr\u00E1t \u00FA\u010Dinn\u011Bj\u0161\u00ED proti enoxaparinu, v p" . . "Prevence a l\u00E9\u010Dba tromboembolick\u00E9 nemoci 2011"@cs . . "1212-7299" . . "13" . "Prevention and treatment of thromboembolic disease 2011"@en . "12" . "V" . "11120" . "Intern\u00ED medic\u00EDna pro praxi" . "CZ - \u010Cesk\u00E1 republika" . . "Prevence a l\u00E9\u010Dba tromboembolick\u00E9 nemoci 2011"@cs . . .